Combined Liver And Kidey Tonic Side Pifibedil The Treatment Of Advanced Parkinson's Disease Dinical Study

Objective:To observe the combined liver and kidney tonic side Piribedil the treatment of advanced Parkinson'sdisease clinical efficacy.Methods:The 60 patients met the inclusion criteria of advanced Parkinson's disease (PD) were randomly divided into two groups, one treatment group and control group,30 cases, The two groups in age, gender, disease duration, underlying diseases, TCM syndrome score distribution, UPDRS score on the basic balance, the statistical analysis, no significant difference (p<0.05), comparable. The treatment group received Piribedil release tablets (The initial measurement of 50mg/d, according to the disease severity, increased every week 50mg, increased to 150mg-250mg/d, the effective dose to maintain the dose), and be in the prescription of oral liver and kidney tonic. Control group, only to be Piribedil oral sustained-release tablets (The initial measurement of 50mg/ d, according to the disease severity, increased every week 50mg, increased to 150mg-250mg/d, the effective dose to maintain the dose). Course of treatment was 6 months. All patients before treatment and after treatment for unified PD rating scale (UPDRS) score, TCM syndrome score and Hoehn & Yahr stage by a professional neurologist to evaluate.Results:After treatment, UPDRS score, TCM syndrome score and Hoehn & Yahr stage, scores were significantly lower than before treatment (p<0.05), but the treatment group lower than control group, and the total effective rate in treatment group than the control Group (p<0.05)Conclusion:The combined liver and kidney tonic medicine Piribedil the treatment of advanced Parkinson's disease a significant effect, and can reduce Piribedil adverse reactions, is worthy of clinical use.